CN102453037B - Isosorbitol derivative and liquid crystal display containing same - Google Patents
Isosorbitol derivative and liquid crystal display containing same Download PDFInfo
- Publication number
- CN102453037B CN102453037B CN201010529434.2A CN201010529434A CN102453037B CN 102453037 B CN102453037 B CN 102453037B CN 201010529434 A CN201010529434 A CN 201010529434A CN 102453037 B CN102453037 B CN 102453037B
- Authority
- CN
- China
- Prior art keywords
- liquid crystal
- solution
- derivative
- grams
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004973 liquid crystal related substance Substances 0.000 title claims abstract description 28
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical class O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 39
- 239000000758 substrate Substances 0.000 claims description 9
- 239000004986 Cholesteric liquid crystals (ChLC) Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 7
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 229910052736 halogen Inorganic materials 0.000 abstract description 5
- 125000005843 halogen group Chemical group 0.000 abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 229960002479 isosorbide Drugs 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 8
- 239000002019 doping agent Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 (4-carboxyl-phenyl)-piperazine-1-carboxylic acid-p-tolyl ester Chemical compound 0.000 description 2
- UCFZVQHKTRSZMM-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)benzoic acid Chemical compound C1CN(C)CCN1C1=CC=C(C(O)=O)C=C1 UCFZVQHKTRSZMM-UHFFFAOYSA-N 0.000 description 2
- PSSZLZXWLSTNGN-UHFFFAOYSA-N 4-(4-pentylpiperazin-4-ium-1-yl)benzoate Chemical compound C1CN(CCCCC)CCN1C1=CC=C(C(O)=O)C=C1 PSSZLZXWLSTNGN-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 0 CCCC(C)*(CC1)CCN1c(cc1)ccc1C(OC(COC12)C1OCC2OC(c(cc1)ccc1N(CC1)CCN1C(C)CCC)=O)=O Chemical compound CCCC(C)*(CC1)CCN1c(cc1)ccc1C(OC(COC12)C1OCC2OC(c(cc1)ccc1N(CC1)CCN1C(C)CCC)=O)=O 0.000 description 2
- 239000004988 Nematic liquid crystal Substances 0.000 description 2
- MCQUUYBUYPRWNR-UHFFFAOYSA-N 4-(4-cyanopiperazin-1-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1CCN(C#N)CC1 MCQUUYBUYPRWNR-UHFFFAOYSA-N 0.000 description 1
- FQAGWVDLXJDTSW-UHFFFAOYSA-N 4-[4-(4-methylphenoxy)carbonylpiperazin-1-yl]benzoic acid Chemical compound C1=CC(C)=CC=C1OC(=O)N1CCN(C=2C=CC(=CC=2)C(O)=O)CC1 FQAGWVDLXJDTSW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention relates to an isosorbitol derivative, wherein it has the following chemical formulas (I): FORMULA, wherein Z is -CH2-CH2-, -CH=CH-, -C is equivalent to C-, -CH2-O-, -CH2-S-, -CH=N-O-, -CO-O-, -CO-S-, a single bond, -ph-, -CO-O-ph- or -CO-O-ph-CO-O-, wherein ph is a phenylene radical; R1 and R2 are independently to be alkyls, -CN, -NCS, -CH3 or -OCX3, which have 1-25 carbons, wherein X is halogen; m and n are independently to be 0, 1 or 2. The invention also provides a liquid crystal display containing the isosorbitol derivative.
Description
Technical field
The present invention relates to a kind of isosorbide (isosorbide) derivative, particularly relates to a kind of isosorbide derivative that is doped in liquid-crystal display.
Background technology
In recent years, due to the prosperity of liquid crystal industry, reason answers the liquid crystal material of various different demands to be developed successively, wherein, cholesteryl liquid crystal (cholesteric liquid crystal) is owing to having bistability (bistability), and in without impressed voltage situation, still can keep Picture Showing, therefore, have an opportunity to become plane technique of display of new generation.
Cholesteric liquid crystal material has had spirane structure and liquid crystal characteristic concurrently.Its spirane structure is normally doped in chiral dopant (chiral dopant) in the cholesteric liquid crystal molecules of not being with chirality and forms.Therefore, the screw twisted power of chiral molecules (helical twisting power, HTP) is the principal element that determines cholesteryl liquid crystal screw twisted degree.In general, every kind of chiral structure has its different HTP.
Chiral dopant is a kind of optically active substance.When chiral dopant is added to tool to the liquid crystal of row (nematic) phase, can make liquid crystal rotation become cholesteryl liquid crystal phase.Screw twisted power (HTP) size of chiral molecules is mainly the characteristic that depends on chiral dopant itself, but also can be subject to as the impact of main nematic liquid crystal material (nematic liquid crystal host) and temperature simultaneously.
Summary of the invention
The object of the present invention is to provide a kind of novel cpd that can be used for cholesteric liquid crystal display.
In one embodiment of the present invention, provide a kind of isosorbide derivative, there is following chemical formula (I):
Wherein Z is-CH
2-CH
2-,-CH=CH-,-C ≡ C-,-CH
2-O-,-CH
2-S-,-CH=N-O-,-CO-O-,-CO-S-, singly-bound ,-ph-,-CO-O-ph-or-CO-O-ph-CO-O-, wherein ph is penylene base; R
1with R
2be alkyl ,-CN ,-the NCS ,-CX of carbon number 1～25 independently
3or-OCX
3, wherein X is halogen; And m and n are 0,1 or 2 independently.
In one embodiment of the present invention, provide a kind of liquid-crystal display, comprising: a upper substrate; One hypocoxa, is oppositely arranged with this upper substrate; And a liquid crystal layer, be arranged between this upper substrate and this hypocoxa, comprise an isosorbide derivative, there is following chemical formula (I):
Wherein Z is-CH
2-CH
2-,-CH=CH-,-C ≡ C-,-CH
2-O-,-CH
2-S-,-CH=N-O-,-CO-O-,-CO-S-, singly-bound ,-ph-,-CO-O-ph-or-CO-O-ph-CO-O-, wherein ph is penylene base, R
1with R
2be alkyl ,-CN ,-the NCS ,-CX of carbon number 1～25 independently
3or-OCX
3, wherein X is halogen, and m and n are 0,1 or 2 independently.
The present invention develops a kind of isosorbide derivative chiral dopant of novelty, and its core texture is made up of an isosorbide, and connects structure using piperazine as its side chain.Isosorbide derivative of the present invention confirms effectively to promote the temperature stability (for example can make its temperature dependency (temperature dependence) be less than or equal 0.2nm/ DEG C) of for example cholesteryl liquid crystal after test, separately, this isosorbide derivative also has larger screw twisted power (HTP) and (for example can be greater than 45 μ m
-1), there is suitable help for the screw twisted degree that promotes cholesteryl liquid crystal.
For above-mentioned purpose of the present invention, feature and advantage can be become apparent, a preferred embodiment cited below particularly, is described in detail below:
Embodiment
One embodiment of the invention, provide a kind of isosorbide derivative, have following chemical formula (I):
In chemical formula (I), can be-CH of Z
2-CH
2-,-CH=CH-,-C ≡ C-,-CH
2-O-,-CH
2-S-,-CH=N-O-,-CO-O-,-CO-S-, singly-bound ,-ph-,-CO-O-ph-or-CO-O-ph-CO-O-, above-mentioned ph represents penylene base.
R
1with R
2can be alkyl ,-CN ,-the NCS ,-CX of carbon number 1～25 independently
3or-OCX
3, above-mentioned X represents halogen.
M and n can be 0,1 or 2 independently.
Below enumerate the particular instance of isosorbide derivative of the present invention:
(compd A-2C1),
(compd A-2C5),
(compd A-2IC5),
(compd A-2BC5),
(compd A-C1C5),
(compd A-2aBC1),
(compd A-2CN),
(compd A-2CF3).
One embodiment of the invention, provide a kind of liquid-crystal display, comprise a upper substrate, one hypocoxa, is oppositely arranged with upper substrate, and a liquid crystal layer, be arranged between upper substrate and hypocoxa, comprise an isosorbide derivative, there is following chemical formula (I):
In chemical formula (I), can be-CH of Z
2-CH
2-,-CH=CH-,-C ≡ C-,-CH
2-O-,-CH
2-S-,-CH=N-O-,-CO-O-,-CO-S-, singly-bound ,-ph-,-CO-O-ph-or-CO-O-ph-CO-O-, above-mentioned ph represents penylene base.
R
1with R
2can be alkyl ,-CN ,-the NCS ,-CX of carbon number 1～25 independently
3or-OCX
3, above-mentioned X represents halogen.
M and n can be 0,1 or 2 independently.
Isosorbide derivative of the present invention can be doped in the liquid-crystal display of for example cholesteryl liquid crystal.
The present invention develops a kind of isosorbide derivative chiral dopant of novelty, and its core texture is made up of an isosorbide, and connects structure using piperazine as its side chain.Isosorbide derivative of the present invention confirms effectively to promote the temperature stability (for example can make its temperature dependency be less than or equal 0.2nm/ DEG C) of for example cholesteryl liquid crystal after test, separately, this isosorbide derivative also has larger screw twisted power (HTP) and (for example can be greater than 45 μ m
-1), there is suitable help for the screw twisted degree that promotes cholesteryl liquid crystal.
[embodiment]
Synthetic 1 of [embodiment 1] isosorbide derivative of the present invention
Compd A-2C1
First, by 4-[4-methyl-piperazine-1-yl of 2.2 grams]-phenylformic acid (4-[4-Methyl-piperazin-1-yl]-benzoic acid) (10mmol) and 2.43 grams 1; 1 "-carbonyl dimidazoles (1; 1 "-Carbonyldiimidazole, CDI) (15mmol) be placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, in nitrogen (N
2) under environment, squeeze into the anhydrous tetrahydro furan (THF) of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride (NaH), complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol (MeOH) to carry out recrystallization, can obtain the compd A-2C1 of 1.15 grams, productive rate 70%, outward appearance is white solid.
Synthetic 2 of [embodiment 2] isosorbide derivative of the present invention
Compd A-2C5
First, by 4-[4-amyl group-piperazine-1-yl of 2.76 grams]-phenylformic acid (4-[4-Pentyl-piperazin-1-yl]-benzoic acid) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, in nitrogen (N
2) under environment, squeeze into the anhydrous tetrahydro furan (THF) of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) (THF) to dissolve it.Afterwards, add sodium hydride (NaH), complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol (MeOH) to carry out recrystallization, can obtain the compd A-2C5 of 1.25 grams, productive rate 63%, outward appearance is white solid.
Synthetic 3 of [embodiment 3] isosorbide derivative of the present invention
Compd A-2IC5
First, by the 4-[4-of 2.76 grams (1-methyl-butyl)-piperazine-1-yl]-phenylformic acid (4-[4-(1-Methyl-butyl)-piperazin-1-y1]-benzoic acid) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol to carry out recrystallization, can obtain the compd A-2IC5 of 1.29 grams, productive rate 65%, outward appearance is white solid.
Synthetic 4 of [embodiment 4] isosorbide derivative of the present invention
Compd A-2BC5
First, by the 4-[4-of 3.52 grams (4-amyl group-phenyl)-piperazine-1-yl]-phenylformic acid (4-[4-(4-Pentyl-phenyl)-piperazin-1-y1]-benzoic acid) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol to carry out recrystallization, can obtain the compd A-2BC5 of 1.61 grams, productive rate 66%, outward appearance is white solid.
Synthetic 5 of [embodiment 5] isosorbide derivative of the present invention
Compd A-C1C5
First, by 4-[4-methyl-piperazine-1-yl of 2.2 grams]-phenylformic acid (4-[4-Methyl-piperazin-1-yl]-benzoic acid) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 1.9 grams (13mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, carry out tubing string chromatography (using ethyl acetate EA: normal hexane HEX=1: 1 as extract), obtain the intermediate (6mmol) of 2.1 grams, productive rate 66%.
Afterwards, by 4-[4-amyl group-piperazine-1-yl of 2.21 grams]-phenylformic acid (4-[4-Pentyl-piperazin-1-yl]-benzoic acid) (8mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of C solution.
Then, above-mentioned intermediate is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of D solution.After two hours, above-mentioned C solution is poured in D solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol to carry out recrystallization, can obtain the compd A-C1C5 of 1.83 grams, productive rate 50%, outward appearance is white solid.
Synthetic 6 of [embodiment 6] isosorbide derivative of the present invention
Compd A-2aBC1
First, by the 4-of 3.40 grams (4-carboxyl-phenyl)-piperazine-1-carboxylic acid-p-tolyl ester (4-(4-Carboxy-phenyl)-piperazin-1-carboxylic acid-p-tolyl ester) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol to carry out recrystallization, can obtain the compd A-2aBC1 of 1.54 grams, productive rate 65%, outward appearance is white solid.
Synthetic 7 of [embodiment 7] isosorbide derivative of the present invention
Compd A-2CN
First, by the 4-of 2.31 grams (4-cyano group-piperazine-1-yl)-phenylformic acid (4-(4-cyano-piperazin-1-yl)-benzoic acid) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol to carry out recrystallization, can obtain the compd A-2CN of 0.9 gram, productive rate 68%, outward appearance is white solid.
Synthetic 8 of [embodiment 8] isosorbide derivative of the present invention
Compd A-2CF3
First, by the 4-of 2.74 grams (4-trifluoromethyl-piperazine-1-yl)-phenylformic acid (4-(4-Trifluoromethyl-piperazin-1-yl)-benzoic acid) (10mmol) and 2.43 grams 1,1 "-carbonyl dimidazoles (CDI) (15mmol) is placed in two neck round-bottomed bottles of 100 milliliters.Afterwards, under nitrogen environment, squeeze into the anhydrous tetrahydro furan of 30 milliliters., after four hours, put to room temperature in reflux, complete the preparation of A solution.
Then, the isosorbide of 0.45 gram (3mmol) is placed in to another round-bottomed bottle, and under ice bath, adds tetrahydrofuran (THF) to dissolve it.Afterwards, add sodium hydride, complete the preparation of B solution.After two hours, above-mentioned A solution is poured in B solution, and be stirred to room temperature approximately two hours.After draining, can obtain yellow solid.Then, use methyl alcohol to carry out recrystallization, can obtain the compd A-2CF3 of 1.18 grams, productive rate 60%, outward appearance is white solid.
Screw twisted power (HTP) and the temperature dependency of [embodiment 9] isosorbide derivative of the present invention
The relevant physicochemical characteristic of isosorbide derivative of the present invention (compd A-2C1, A-2C5, A-2IC5, A-2BC5, A-C1C5, A-2aBC1, A-2CN, A-2CF3), for example screw twisted power (helicaltwisting power, HTP) and temperature dependency (temperature dependence, d λ/dT) be shown in following table 1.Measuring temperature is 20～50 DEG C.
Table 1
As seen from Table 1, isosorbide derivative of the present invention (compd A-2C1, A-2C5, A-2IC5, A-2BC5, A-C1C5, A-2aBC1, A-2CN, A-2CF3) has larger screw twisted power (HTP), for example, be all greater than 45 μ m
-1, and its temperature dependency is low, for example, be all less than or equal to 0.2nm/ DEG C, therefore, is quite applicable to being applied to the liquid-crystal display of for example cholesteryl liquid crystal.
Although the present invention discloses as above with preferred embodiment; so it is not in order to limit the present invention, anyly has the knack of this skill person, without departing from the spirit and scope of the present invention; when doing to change and retouching, the scope that therefore protection scope of the present invention ought define depending on accompanying claim is as the criterion.
Claims (3)
1. an isosorbide derivative, it one of is following compound:
2. a liquid-crystal display, comprising:
One upper substrate;
One hypocoxa, is oppositely arranged with this upper substrate; And
One liquid crystal layer, is arranged between this upper substrate and this hypocoxa, comprises an isosorbide derivative as claimed in claim 1.
3. liquid-crystal display as claimed in claim 2, wherein this liquid-crystal display is cholesteric liquid crystal display.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010529434.2A CN102453037B (en) | 2010-10-25 | 2010-10-25 | Isosorbitol derivative and liquid crystal display containing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010529434.2A CN102453037B (en) | 2010-10-25 | 2010-10-25 | Isosorbitol derivative and liquid crystal display containing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102453037A CN102453037A (en) | 2012-05-16 |
| CN102453037B true CN102453037B (en) | 2014-06-25 |
Family
ID=46036762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010529434.2A Expired - Fee Related CN102453037B (en) | 2010-10-25 | 2010-10-25 | Isosorbitol derivative and liquid crystal display containing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102453037B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022969A (en) * | 1994-09-23 | 2000-02-08 | Axys Pharmaceuticals, Inc. | Compositions and methods for treating mast-cell mediated conditions |
| CN1394862A (en) * | 2001-07-02 | 2003-02-05 | 默克专利股份有限公司 | Chiral compound |
| CN1715309A (en) * | 2005-07-22 | 2006-01-04 | 东北大学 | Thermotropic front cholesteric liquid crystal polymer and its preparing method |
| TW200825158A (en) * | 2006-12-12 | 2008-06-16 | Ind Tech Res Inst | Additive for liquid crystal having high helical twisting power, synthesis method thereof and a liquid crystal composition containing the additive |
| EP2028253A1 (en) * | 2007-08-24 | 2009-02-25 | Chisso Corporation | Optically isotropic liquid crystal medium and optical device |
| CN101479362A (en) * | 2006-06-27 | 2009-07-08 | 西柏控股有限公司 | Cholesteric multi-layers |
-
2010
- 2010-10-25 CN CN201010529434.2A patent/CN102453037B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022969A (en) * | 1994-09-23 | 2000-02-08 | Axys Pharmaceuticals, Inc. | Compositions and methods for treating mast-cell mediated conditions |
| CN1394862A (en) * | 2001-07-02 | 2003-02-05 | 默克专利股份有限公司 | Chiral compound |
| CN1715309A (en) * | 2005-07-22 | 2006-01-04 | 东北大学 | Thermotropic front cholesteric liquid crystal polymer and its preparing method |
| CN101479362A (en) * | 2006-06-27 | 2009-07-08 | 西柏控股有限公司 | Cholesteric multi-layers |
| TW200825158A (en) * | 2006-12-12 | 2008-06-16 | Ind Tech Res Inst | Additive for liquid crystal having high helical twisting power, synthesis method thereof and a liquid crystal composition containing the additive |
| EP2028253A1 (en) * | 2007-08-24 | 2009-02-25 | Chisso Corporation | Optically isotropic liquid crystal medium and optical device |
Non-Patent Citations (4)
| Title |
|---|
| Dibasic inhibitors of human mast cell tryptase. Part 2: Structure–activity relationships and requirements for potent activity;Kenneth D.Rice,等;《Bioorganic and Medicinal Chemistry Letters》;20001016;第10卷(第20期);第2361–2366页 * |
| Johan Lub,等.Sythesis and properties of photoisomerizable derivatives of isosorbide and their use in chloesteric filters.《Advanced functional Materials》.2005,第15卷(第12期),第1961-1972页. |
| Kenneth D.Rice,等.Dibasic inhibitors of human mast cell tryptase. Part 2: Structure–activity relationships and requirements for potent activity.《Bioorganic and Medicinal Chemistry Letters》.2000,第10卷(第20期),第2361–2366页. |
| Sythesis and properties of photoisomerizable derivatives of isosorbide and their use in chloesteric filters;Johan Lub,等;《Advanced functional Materials》;20051231;第15卷(第12期);第1961-1972页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102453037A (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102585840B (en) | Liquid crystal composition containing cyclopentyl compounds | |
| CN104449761A (en) | Liquid crystal compound containing difluoromethoxy bridged bonds and application thereof | |
| CN104087312A (en) | Liquid crystal composition and its application | |
| CN102795974B (en) | Liquid crystal medium and liquid crystal composition | |
| JP5392256B2 (en) | Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device | |
| CN102947262A (en) | Compound having branched alkyl or branched alkenyl, optically isotropic liquid crystal medium and optical element | |
| CN104059674A (en) | Liquid crystal composition containing difluoromethoxy bridged bond and application thereof | |
| CN102746854A (en) | Negative dielectric anisotropy liquid crystal composition | |
| TW201217502A (en) | Liquid crystal composition and liquid crystal display employing the same | |
| CN104003964A (en) | Liquid crystal compound containing tetrahydropyrane ring and application of Liquid crystal compound | |
| JP4691893B2 (en) | Liquid crystal composition, display element and compound containing trifluoronaphthalene derivative. | |
| TWI414527B (en) | Isosorbide derivatives and liquid crystal displays comprising the same | |
| CN102453037B (en) | Isosorbitol derivative and liquid crystal display containing same | |
| EP1957611B1 (en) | Temperature compensating chiral dopants | |
| KR100197449B1 (en) | Chiral doping agents for liquid crystals | |
| US4585575A (en) | 2-substituted-6-(5-substituted-2-pyrimidinyl)naphthalenes | |
| CN110437846B (en) | Fluorine substituted benzoxazole liquid crystal compound containing acetylene bond and preparation method thereof | |
| CN102557929A (en) | Chiral bis-naphthyl compounds | |
| Lee et al. | Synthesis of cyclopentyloxy terphenyl liquid crystals with negative dielectric anisotropy | |
| CN102140349A (en) | Pyridine liquid crystal composition for TFT display | |
| TWI447211B (en) | Chiral compound with isosorbide moiety and chiral composition and blue phase liquid christal composition thereof | |
| TWI691483B (en) | Chiral dopants having a nortricyclan unit | |
| JP4940560B2 (en) | Liquid crystal composition, display element and compound containing trifluoronaphthalene derivative | |
| US5462695A (en) | Chiral liquid crystal materials as dopant for ferroelectric liquid crystal compositions | |
| CN104830347B (en) | The liquid-crystal compounds of the dioxane ring containing 4,6 dimethyl 1,3, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 |